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ABSTRACT 
In this article, the history of the microbiota is reviewed 
and the related concepts of the microbiota, microbiome, 
metagenome, pathobiont, dysbiosis, holobiont, phylotype 
and enterotype are defined. The most precise and current 
knowledge about the microbiota is presented and the met-
abolic, nutritional and immunomodulatory functions are 
reviewed. Some gastrointestinal diseases whose pathogen-
esis is associated with the intestinal microbiota, including 
inflammatory bowel disease, irritable bowel syndrome and 
celiac disease, among others, are briefly discussed. Final-
ly, some prominent and promising data with regard to the 
fecal microbiota transplantation in certain digestive illness 
are discussed. 
Key words: Microbiota. Microbiome. Metagenome. Dysbi-
osis. Phylotype. Enterotype.
FROM THE INTESTINAL FLORA  
TO THE MICROBIOME
In 1683, Anton van Leeuwenhoek described some “animal-
cules” he had observed in the gastrointestinal tract under 
a microscope that he himself had made, unaware that he 
was making the first description of the appearance of a 
bacterium (1). Since then significant progress has been 
made. Almost two centuries later, in 1861, Louis Pasteur, 
the brilliant French bacteriologist, discovered anaerobic 
intestinal bacteria (2). Pasteur himself is credited with the 
thought “The role of the infinitely small in nature is infinite-
ly large” (3).
Ilya Metchnikov, a Ukrainian scientist who won the Nobel 
Prize in 1908 and a professor at the Pasteur Institute in Paris, 
had previously proposed that the so-called lactic acid bac-
teria (LAB) provided health benefits and were in some way 
capable of promoting human longevity. He suggested that 
the so-called “intestinal autointoxication” and the result-
ing effect on aging could be suppressed by modifying the 
intestinal flora. By replacing proteolytic microbes, such as 
Clostridium (which produce toxic substances such as phe-
nols, indoles and ammonia via the digestion of proteins) 
with useful microbes such as Lactobacillus (4).
The term microbiome was coined in 2001 by Joshua Leder-
berg, an American molecular biologist. He was one of the 
three researchers who won the Nobel Prize in Medicine in 
1958, awarded for their work in genetic studies of bacte-
ria. Lederberg stated that symbiotic microorganisms and 
humans form a great metabolic unit, a view which recog-
nizes that the bacteria located within the human body are in 
fact protecting us (5). In recent years, biomedical research 
has led to advances in our knowledge of the gut microbiota 
(referred to as intestinal flora until 2014). However, there is 
still a great deal to learn, much more than what we have 
already learnt during the last three centuries.
Over the last few years, two major projects have been 
decoding the structure and functionality of the human 
microbiota, as well as its relation to disease. The MetaHIT 
(Metagenomics of the Human Intestinal Tract; www.metahit.
eu), funded by the European Union, and the Human Micro-
biome Project (http://hmpdacc.org), funded by the National 
Institute of Health of the United States of America.
Building on the article “Microbiota and the gastrointestinal 
system”, by C. Barbés Miguel, which was published in 2001 
in the Point of View section of this journal (6), this review 
provides an update with some of the knowledge acquired 
during the past 16 years about this exciting organism. 
Before going further, it is important to define the terms that 
will be used in this article, along with the already known 
nomenclature of prebiotic, probiotic and symbiotic: micro-
biota, microbiome, metagenome, pathobiont, dysbiosis 
and holobiont (7).
Microbiota refers to the community of living microorgan-
isms residing in a particular ecological niche, such as the 
human gut (colon). The microbiome is the ensemble formed 
by microorganisms, their genes and their metabolites in a 
given ecological niche. About 9.9 million microbial genes 
have been identified in the human fecal microbiome (8). 
The metagenome refers to all the genetic material pres-
ent in an environmental sample, which in this case is the 
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entire human and bacterial (microbial, in general) genome. 
Pathobiont are benign endogenous microbes with the abil-
ity, under the conditions of an altered ecosystem (dysbio-
sis), to cause certain pathologies. Dysbiosis is the loss of 
balance between the cells of a human organism and the 
bacterial (microbial, in general) cells that inhabit it. Finally, 
the holobiont, also known as the superorganism, refers to 
the totality of organisms in a given ecosystem (in this case, 
humans and the shared microbial ecosystem). Humans are 
in fact superorganisms governed in part by the microorgan-
isms we host (9).
The microbiota has become fashionable. It no longer only 
interests the medical profession but also readers of the 
general press, such as El País. In the Sunday supplement 
of El País on the 8th of January 2017 (http://elpaissemanal.
elpais.com/documentos/viaje-nuestras-profundidades/), 
Juan José Millás published an article-interview entitled 
“Viaje a nuestras profundidades: en el intestino está la 
clave”. Within this article, some of the current knowledge 
of the human gut and microbiota was reviewed with great 
accuracy and precision by professor Carlos López-Otín, the 
renowned Aragonese scientist and professor of Biochemis-
try and Molecular Biology in the Faculty of Medicine at the 
University of Oviedo.
The Journal of the International Microbial Society (JISM), 
dedicated to covering a variety of new strategies and inno-
vations in the field as well as clinical applications derived 
from studies on gut microbiota, is another indicator of the 
wider interest in this subject. The Fifth World Congress of 
the International Society of Microbiota (https://www.micro-
biota-site.com/) was held in October 2017 in Berlin, under 
the banner “Targeting Microbiota”.
The vast majority, more than 90%, of bacteria present in the 
human system reside in the colon. The quantity was previ-
ously estimated to be around 1014, i.e., about 100 billion (10). 
Recent studies using much more precise techniques have 
concluded that the volume of bacteria in the colon is less, 
around 1011 per gram. Considering that the volume of the 
colon is around 0.4 l or kg (400 g), it can be concluded that 
there are around 3.8 x 1013 (38 billion) bacteria in the colon 
(11) of a “typical male”. This is defined as a male between 
20 and 30 years old, weighing around 70 kg and 170 cm tall 
(12). Reviews of the literature suggest that bacterial concen-
trations in the colon do not appear to modify significantly 
over time, from childhood to old age (13).
With regard to the number of human cells in a typical adult 
male, the quantity is estimated at 3.0 x 1013 or about 30 
billion, of which 84% (25 x 1012) are erythrocytes (11). One 
might think that man is little more than a transporter of 
bacteria. With these updated numbers, the ratio between 
bacteria and human cells has fallen to approximately 1.3:1 
(in a 70 kg male). Almost a 1:1 ratio, which should replace 
the values of 10:1 (14) or 100:1 which were quoted in the 
literature before more accurate measurements became 
available (11).
It has also been estimated that the total mass/weight of 
the bacteria in the colon is approximately half the weight 
of the colon itself, which is about 200 g (50 to 100 g dry 
weight) as the colon weighs close to 400 g (15). The weight 
of the colon thus represents 0.3% of the total body weight, 
a figure significantly lower than the 1-3% (with 1 to 2 kg of 
the total body weight attributed to bacterial mass) that the 
colon was believed to comprise until recently (11).
The gut microbiome is immensely diverse. It hosts more 
than 1,000 different bacterial species (16), mainly anaerobic 
bacteria (17). According to some studies, the number and 
diversity of these increase with the age of the host. While 
other studies suggest the opposite, a reduction and loss 
of diversity of the microbiota over time, with deficient and 
dysbiotic functioning influenced by age, environmental fac-
tors and lifestyle (18).
The microbiome is defined mainly by two bacterial filo-
types, Firmicutes and Bacteroidetes (the latter accounting 
for 90% of the gut microbiota), and to a lesser extent, Act-
inobacteria. The first of these includes a large number of 
genera, the most important are Lactobacillus and Clostrid-
ium. Bacteroides include bacteria belonging to the genus 
Bacteroides and Prevotella. The main genus belonging to 
the Actinobacteria phylum in the human intestine is Bifido-
bacterium (19). The phylotype is a taxonomic group defined 
by the degree of similarity between DNA sequences of the 
16S gene and not by phenotypic characteristics.
An important advance in the knowledge of the gut micro-
biota occurred in 2011, when the enterotypes were defined 
in adults (20) as the different groups of gut microbiota in 
accordance with certain states of equilibrium. Each entero-
type is differentiated by the variation of the presence of 
the three predominant bacterial genera: Bacteroides (type 
1 enterotype), Prevotella (type 2 enterotype) and Rumino-
coccus (type 3 enterotype), which are probably related to 
long-standing dietary patterns. The type 1 enterotype is 
associated with a diet rich in protein and fat and type 2 
with carbohydrate consumption (21). The category seems 
to be independent of gender, age, nationality or body mass 
index. The type 1 enterotype is the most prevalent in Euro-
pean subjects, appearing in 56% of subjects followed by 
type 2, at 31% (22). 
Previously, bacterial diversity studies were mainly carried 
out via culture techniques, which provided a biased view 
of the bacterial composition of the fecal microbiota. The 
subsequent development of high-throughput sequencing 
techniques as well as the development of bioinformatic 
tools has led to a comprehensive description of the bacte-
rial community that inhabits the gastrointestinal tract and 
has been a turning point with regard to the understanding 
of bacterial colonization of the human gut. Our colleague 
Francisco Guarner M.D., of the Vall d’Hebron Hospital in 
Barcelona (22), has played a prominent role in this field.
The functional aspects of the normal human gut microbiota 
comprise the following: metabolic and nutritional functions, 
antimicrobial protection, maintenance of the integrity of the 
intestinal mucosa and regulation of the immune response 
(23-25).
With regard to the metabolic functions, the following 
should be emphasized: 
1.  Anaerobic bacterial fermentation of dietary fiber car-
bohydrates leads to the formation of short chain fatty 
acids (SCFA), which are the preferred respiratory fuel 
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for the colonocites. These SCFA have an anti-inflam-
matory effect as they inhibit certain pro-inflamma-
tory cytokines and, interestingly, are able to induce 
apoptosis of malignant colon cancer cells (26). The 
SCFA produced by carbohydrate fermentation include 
acetate, propionate and butyrate, which are absorbed 
by the colon (23). The majority of the propionate is 
metabolized by the liver, where it acts to reduce se-
rum cholesterol and glucose levels (27). Butyrate is 
the major provider of energy to cells in the colonic 
epithelium. The SCFA promote the integrity of cell 
junctions in the colon, increase the rate of prolifera-
tion of epithelial cells, accelerate epithelial repair in 
response to injury and facilitate the differentiation of 
epithelial cells, with the consequential effects against 
colon cancer (28).
2.  The gut microbiota has recently been identified as 
a new factor involved in the management of body 
weight. The microbiota is involved in energy metab-
olism via the energy obtained from the diet, specif-
ically, in the regulation of the storage of body fat, 
the regulation of lipogenesis and the regulation of 
the oxidation of fatty acids (23,29). Current evidence 
suggests that certain changes in the gut microbiota, 
in particular an increase in Firmicutes and a decrease 
in Bacteroidetes (30), play an important role in the 
development and maintenance of obesity, probably 
interacting with genetic factors. In addition to many 
other mechanisms (31), one of the most important 
factors that contributes to obesity includes a higher 
energy intake from the colon via the fermentation of 
non-absorbable carbohydrates (23). In contrast, the 
gut microbiota may also play a decisive role in an-
orexia nervosa and the severe weight loss resulting 
from this condition, as well as the associated mental 
disorders, anxiety and depression (31).
3.  The gut microbiota synthesizes vitamin K and several 
components of vitamin B, including vitamin B12 (24,32). 
However, the latter is unlikely to be available directly 
to the human host due to the physiology of its absorp-
tion, which requires binding to factor R in the stomach, 
transfer to the intrinsic factor in the small bowel and 
absorption of the complex in the terminal ileum.
With regard to immunomodulation or the regulation of the 
immune response, in healthy subjects, the microbiota is in 
homeostatic symbiosis with the host via a functional intes-
tinal epithelial barrier that contains high concentrations of 
secretory IgA (IgA S). The latter is produced by the plasma 
cells located in the Peyer’s plaques and forms complexes 
in the lamina propia with the commensal bacteria and the 
microbiota in the intestinal lumen and selectively present 
the bacterial components to the dendritic cells. These cells 
induce the production of anti-inflammatory interleukin 10 
(IL-10), which contributes to a class change from IgA S to 
IgA. All of this ensures effective communication between 
the microbiota and the immune system, inducing a tolero-
genic environment towards the microbiota and, at the same 
time, stimulating the activity of the immune system (33,34). 
The composition of the microbiota helps to maintain immu-
nological homeostasis, which suggests that the microbiota 
could be an additional organ of the human organism (35).
The microbiota-gut-brain axis is a bidirectional system that 
should be added to this complex. In one direction, the brain 
may indirectly affect the gut microbiota via changes in secre-
tion, motility and/or intestinal permeability. In addition, it 
may directly influence the microbiota via neuronal networks 
through the release of substances by the enterocromaffin 
and immune cells. In the other direction, the gut microbiota 
communicates with the brain by direct stimulation of certain 
receptors, via vagal afferents or via the recently described 
humoral pathway. All of this can alter brain morphology 
and neurochemistry and specifically GABA and serotonin 
levels. This microbiota-brain communication is involved in 
the perception of visceral pain (36) and in the modulation 
of the immune response and emotions (37,38).
 Below is a brief review of some gastrointestinal diseases 
whose pathogenesis is associated with the gut microbiota. 
In some cases, such as inflammatory bowel disease and 
irritable bowel syndrome, there is strong evidence support-
ing the implication of the microbiota. However, in others, 
such as celiac disease, the body of evidence suggests a less 
important role. There are also other processes, such as col-
orectal cancer, gastric cancer and hepatocellular carcinoma, 
in which the microbiota seems to be involved.
Inflammatory bowel disease (IBD) is clearly associated with 
intestinal dysbiosis and the gut microbiota seems to play 
a clear role in its pathogenesis. However, it is still unclear 
whether such dysbiosis is causative, contributes to, or is a 
consequence of the disease. It is likely that all three possi-
bilities occur (39,40). More advances are needed in bacterial 
culture and experimental models and a wider implementa-
tion of bioinformatics in order to improve our understand-
ing of the role of the gut microbiota in IBD.
With regards to experimental models, the gnotobiotic 
mouse has a known microbiota obtained from animals free 
from microorganisms and seems to be a useful model to 
investigate the functional role of the IBD-associated dysbi-
otic microbiota. Using this model, it has been shown that 
intestinal dysbiosis may potentially contribute to the patho-
genesis of IBD, increasing the pro-inflammatory immune 
response of the host (41). The data from this study suggests 
that dysbiosis in patients with IBD is a key factor in the 
onset and maintenance of intestinal inflammation and not 
merely a secondary outcome.
A recent meta-analysis (42) found that the mean level of 
Bacteroides was significantly lower in patients with Crohn’s 
disease (CD) and active ulcerative colitis (UC) compared to 
patients in remission and normal controls. Thus, it appears 
that the inflammatory activity in IBD causes a significant 
reduction of Bacteroides.
With regard to irritable bowel syndrome (IBS), gut micro-
biota disturbances have been linked to its pathophysiology 
for many years. The Rome Working Group concluded (43) 
that there is good evidence to support the idea that the gut 
microbiota is altered in IBS. The microbiota participates in 
the different mechanisms involved in the pathophysiology 
of IBS. This includes intestinal and colonic motility, visceral 
sensitivity, intestinal mucosal barrier and neuro-immune 
signals, as well the gut-brain-microbiota axis (44), all of 
which are involved in the pathogenesis of this disorder.
A recent meta-analysis in China (45) confirmed that there 
were alterations in the microbiota in patients with IBS, 
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probably connected to the pathogenesis of IBS. These alter-
ations were different among patients from China, who had 
a decreased number of Bifidobacteria and Lactobacillus and 
a greater number of E. coli and Enterobacterium, with no 
significant change in the quantity of Bacteroides, whereas 
in patients from other regions, such as Europe, there was a 
decrease in the number of Bifidobacteria and a higher num-
ber of Bacteroides. This finding is in line with the differences 
in the enterotype population observed in different regions, 
as discussed at the beginning of this article.
With regard to celiac disease (CeD), both genetic determi-
nants and environmental exposure to gluten are neces-
sary for complete manifestation; neither of these alone is 
enough. Epidemiological and clinical data suggest that oth-
er environmental factors, including infections, alterations in 
the composition of the gut microbiota and type of early diet, 
may also play a role in the development of the disease. This 
interaction is a sine qua non condition for the development 
of CeD. The deterioration of the interaction between micro-
biota, innate immunity and genetic and dietary factors leads 
to the alteration of homeostasis and inflammation, causing 
intestinal tissue damage (46). Differences in the microbial 
composition have been observed between patients with 
CeD and healthy individuals. Different studies also indicate 
that the microbiota may be involved in the manifestation of 
the disease. Some epidemiological studies have indicated 
that several factors influence both the risk of developing 
CeD and the composition of the gut microbiota, strongly 
supporting the link between the microbiota and the onset 
of the disease (47-50). 
Another entity in which the microbiota seems to play an 
important role via different mechanisms is non-alcoholic 
fatty liver disease (51). The microbiota is also implicated 
in colorectal cancer (CRC) (52,53), hepatocellular carci-
noma (54), and gastric cancer (55). However, a thorough 
description of these conditions is beyond the scope of 
this article. 
It is worth mentioning an excellent study by several Span-
ish researchers in the journal Aging (56), which focused on 
an animal model, the Caenorhabditis elegans worm. This 
study showed that worms with a diet rich in Bacillus sub-
tilis (gram positive) lived longer (43 to 58% longer) than 
those with a standard diet rich in Escherichia coli (gram 
negative), even though the latter is more nutritious. The 
difference in longevity seemed to be due to the fact that 
B. subtilis does not synthesize CoQ, an antioxidant that is 
synthesized by E. coli. In this case, the antioxidant seems 
to be harmful. In summary, the study indicated that the 
microbiome may influence life expectancy, i.e., longevity, 
and that, undoubtedly, diet composition affects the health 
of the organism. Yet another reason to continue investiga-
tion into our microbiota. 
To conclude, we would like to briefly mention the possibil-
ities opened by the transplantation of fecal microbiota for 
the treatment of certain gastrointestinal diseases (57,58). 
The efficacy of this process has been clearly demonstrated 
in cases of Clostridium difficile infection (59,60) and it is 
also beginning to be used in cases of IBD (61). While the 
available evidence is still insufficient to recommend the 
procedure, it has shown good results for ulcerative colitis 
(62-64). However, there is still a long way to go. 
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